BORMANN-KENNEDY BARBARA-JEAN ANNE 4

What Happened
Barbara-Jean Anne Bormann-Kennedy, a director of Xeris Biopharma Holdings, sold 16,000 shares in an open-market transaction on June 4, 2026 for total proceeds of $97,507 (weighted average price $6.09). On the same day she was granted 24,193 restricted stock units (RSUs) (no cash cost) and 32,996 stock options reported at $6.15 (aggregate reported value $202,925). The sale was effected under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: June 4, 2026. Form 4 filed June 5, 2026 (next-day filing).
• Sale: 16,000 shares disposed; weighted average sale price reported $6.09; footnote indicates sale prices ranged $5.97–$6.17 and the filer can provide per-price breakdown on request.
• Awards: 24,193 RSUs (reported $0 cash) and 32,996 stock options (reported at $6.15, aggregate $202,925).
• Vesting/conditions: RSUs vest in full upon the earlier of June 4, 2026 or the Company’s next annual meeting, subject to continued service. The stock options have the same vesting trigger.
• Shares owned after transaction: not specified in the provided filing information.
• Notable: Sale was pursuant to a Rule 10b5-1 plan (prearranged trading plan), which is typically used to systematically sell shares and is not an ad-hoc sale.

Context

• The RSU grant represents a contingent right to receive common shares once vesting conditions are met (not an immediate purchase).
• The stock option grant is a derivative award (grant of options) rather than an exercise/cashless sale — options vest on the same schedule and would only convert to shares upon exercise per plan terms.
• Because the sale was under a 10b5-1 plan and grants are routine compensation, these transactions are administrative in nature; they are factual disclosures and do not, by themselves, indicate the director’s view of the company’s prospects.